Abstract
Systemic mastocytosis (SM) is a rare disease caused by an abnormal mast cell accumulation in various tissues. Two classes of constitutive activating c-kit mutations are found in SM. The most frequent class occurs in the catalytic pocket coding region with substitutions at codon 816 and the other in the intracellular juxtamembrane coding region. Therefore, kinase inhibitors that block mutated c-kit activity might be used as therapeutic agents in SM. Here, we show that STI571 inhibits both wild-type and juxtamembrane mutant c-kit kinase activity, but has no effect on the activity of the D816 V mutant. Accordingly, STI571 selectively decreases the survival of normal mast cell and of mast cell lines either with juxtamembrane c-kit mutations, but not that of tumoral mast cell from patient with SM or of mast cell lines with the D816 V mutation. Therefore, STI571 is not a good candidate to treat SM and specific kinase inhibitors should be designed to inhibit constitutive activating mutations at codon 816.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E and Mecucci C . (2000). Blood, 95, 726–727.
Beslu N, LaRose J, Casteran N, Birnbaum D, Lecocq E, Dubreuil P and Rottapel R . (1996). J. Biol. Chem., 271, 20075–20081.
Buchdunger E, Cioffi CL, Law N, Stor FD, Ohno-Jones S, Druker BJ and Lyndon ND . (2000). J. Pharmacol. Exp. Ther., 295, 139–145.
Butterfield JH, Weiler D, Dewald G and Gleich GJ . (1988). Leuk. Res., 12, 345–355.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL . (2001). N. Engl. J. Med., 344, 1031–1037.
Hermine O, Mayeux P, Titeux M, Mitjavila MT, Casadevall N, Guichard J, Komatsu N, Suda T, Miura Y and Vainchenker W . (1992). Blood, 80, 3060–3069.
Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y, Aozasa K and Nomura T . (2000). Cancer Res., 60, 2345–2347.
Horny HP and Valent P . (2001). Leuk. Res., 25, 543–551.
Issaad C, Ahmed M, Novault S, Bonnet ML, Bennardo T, Varet B, Vainchenker W and Turhan AG . (2000). Leukemia, 14, 662–670.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B and Demetri GD . (2001). N Engl. J. Med., 344, 1052–1056.
Kitamura Y, Go S and Hatanaka K . (1978). Blood, 52, 447–452.
Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH and Linch DC . (2001). Blood, 98, 1752–1759.
Longley BJ and Metcalfe DD . (2000). Hematol. Oncol. Clin. North Am., 14, 697–701.
Longley BJ, Metcalf DD, Thrap M, Wang X, Tyrrell L, Lu S-Z, Heitzan D, and Tha Y . (1999). Proc. Natl. Acad. Sci. USA, 96, 1609–1614.
Longley J, Duffy TP and Kohn S . (1995). J. Am. Acad. Dermatol., 32, 545–561.
Marone G, Spadaro G, Granata F and Triggiani M . (2001). Leuk. Res., 25, 583–594.
Tsujimura T, Hashimoto K, Kitayama H, Ikeda H, Sugahara H, Matsumura I, Kaisho T, Terada N, Kitamura Y and Kanakura Y . (1999). Blood, 93, 1319–1329.
Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y and Kanakura Y . (1996a). Blood, 87, 273–283.
Tsujimura T, Moriyama Y, Yamatodani A, Kimura M, Tohya K, Morimoto M, Kitayama H, Kanakura Y and Kitamura Y . (1996b). Am. J. Pathol, 148, 189–200.
Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD . (2001). Oncogene, 20, 5054–5058.
Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW and Bennett JM . (2001). Leuk. Res., 25, 603–625.
Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P and Lechner K . (1992).Blood, 80, 2237–2245.
Worobec AS . (2000). Hematol. Oncol. Clin. North Am., 14, 659–687.
Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R and Naoe T . (2001). Blood, 97, 2434–2439.
Zermati Y, Varet B and Hermine O . (2000). Exp. Hematol., 28, 256–266.
Acknowledgements
This work was supported by grants from the Association Française pour les Initiatives de Recherche sur le Mastocyte et les Mastocytoses (AFIRMM), the Association pour la Recherche sur le Cancer (ARC) and the Ligue Nationale Contre le Cancer (LNCC). We are indebted to Dr A Turhan (IGR, Villejuif, France) who kindly provided the UT-7-bcr-abl cell line, to Dr Y Kanakura (Tokyo, Japan) who kindly provided FMA-3, Dr K Hashimoto for P815, Ba/F3 Kit G559 and IC2KitV814 cell lines, and to Dr Valent for kindly providing the HMCI cell line (Vienna, Austria). We thank A Tu and D Chez for their help in editing this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zermati, Y., De Sepulveda, P., Féger, F. et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22, 660–664 (2003). https://doi.org/10.1038/sj.onc.1206120
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206120
Keywords
This article is cited by
-
Avapritinib in the Treatment of Systemic Mastocytosis: an Update
Current Hematologic Malignancy Reports (2021)
-
Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
Oncogene (2017)
-
Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation
Nature Communications (2014)
-
Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation
Cell Death & Disease (2012)
-
Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders
British Journal of Pharmacology (2008)